Genzyme
Executive Summary
Gains permission from FDA to begin clinical trials for its recombinant beta-glucocerebrosidase for the treatment of Gaucher's disease. The trials will compare r-GCR to the company's naturally- derived Ceredase (alglucerase), the current therapy for Gaucher's disease. . . .